Cystic Fibrosis Foundation invests in Felix Biotechnology

By The Science Advisory Board staff writers

March 7, 2022 -- Felix Biotechnology received a strategic investment from the Cystic Fibrosis Foundation as part of a Therapeutics Development Award. The award will bolster Felix's work on creating a novel therapy to manage chronic Pseudomonas aeruginosa lung infections.

The company said that its phage therapies are specially designed to consider and drive advantageous evolutionary outcomes of phage treatment, resulting in a more durable therapy.

The therapy is currently being evaluated in a clinical trial at Yale University. Felix's discovery and engineering technology platforms are built on technology from Yale and Lawrence Berkeley National Laboratory.

Felix Biotech lands grant for machine learning
Felix Biotechnology was recently awarded a $256,000 Small Business Innovation Research phase I grant by the National Science Foundation to further enhance...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter